Ginkgo Bioworks and Syngenta Seeds Announce Collaboration to Develop New Traits for the Next Generation of Seed Technology
Posted: 19 April 2023 Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity, and Syngenta Seeds, one of the world’s leading agricultural technology companies, announced a research partnership focused on screening a targeted genetic…
Former U.S. Secretary of Veterans Affairs Dr David Shulkin assumes advisory role with 4DMedical
Posted: 19 April 2023 Respiratory imaging technology disruptor 4DMedical Limited announces that Dr David Shulkin, MD, has assumed an advisory role within the company. As an accomplished and prominent health care system leader, physician, academic, and industry entrepreneur,…
Atmo Biosciences strengthens US focus with new board appointment and establishment of San Diego office
Posted: 17 April 2023 Atmo Biosciences, a company commercialising the world’s first ingestible gas-sensing capsule that provides insights into gut health and microbiome function, is strengthening its US focus with the appointment of experienced medical device executive Chris…
Cynata Receives Ethics Committee Approval for Proposed aGvHD Phase 2 Clinical Trial
Posted: 12 April 2023 Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that it has received approval from the Australian Human Research Ethics Committee (HREC) to commence the proposed Phase 2 clinical…
Desperate pain patients spending thousands on unproven stem cell therapies
Posted: 12 April 2023 y Professor David Hunter, Florance and Cope Chair of Rheumatology and Professor of Medicine, University of Sydney and Royal North Shore Hospital Australians living with arthritis pain are parting with thousands of dollars, sometimes tens…
COVID VACCINE INDUCES ROBUST T CELL RESPONSES IN BLOOD CANCER PATIENTS
Posted: 12 April 2023 Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals. Published today in Cell Reports Medicine, the research team, led…
Dose Escalation Approved in ACCENT Clinical Trial of AMP945
Posted: 12 April 2023 Amplia Therapeutics Limited is pleased to advise that following a review of safety data collected to date, the ACCENT clinical trial’s Safety Review Committee has approved dose escalation of AMP945 and recruitment of a…
Iron link offers new treatment hope for incurable blood cancer
Posted: 12 April 2023 A landmark discovery linking iron regulation to a rare blood cancer has led to clinical trials of a potential new treatment for patients with the incurable disease. The study focused on polycythemia vera (PV),…
Resistance-fighting antimalarial drug candidate enters the clinic
Posted: 12 April 2023 A new antimalarial drug candidate, discovered through a longstanding collaboration between WEHI and global biopharmaceutical company MSD has entered Phase 1 clinical testing in healthy participants. The candidate inhibits two essential enzymes required for…
Minister for Industry and Innovation launches new connected health innovation and commercialisation centre in Victoria
Posted: 12 April 2023 The Victorian Connected Health Innovation and Commercialisation Centre (CHICC), powered by ANDHealth, was formally opened today by the Minister for Industry and Innovation, The Hon Ben Carroll MP. The Victorian Government has invested $2.4…
Alterity Therapeutics Enrols First Patient in the United Kingdom in ATH434 Phase 2 Clinical Trial in Multiple System Atrophy
Posted: 12 April 2023 Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the first participant has been dosed in the United Kingdom in the Company’s Phase 2 clinical trial of…
Noxopharm to Prioritise Cutting-Edge ChromaTM & SofraTM Programs
Posted: 6 April 2023 Innovative biotech company Noxopharm Limited (ASX:NOX) announces that as part of the Board and management team’s continual operational risk and cost profile evaluation, the company has reviewed the opportunities for its growing portfolio of…
